Jin Rong Jie·2025-07-31 21:20Group 1 - The stock price of Rongchang Biopharma closed at 64.17 yuan on July 31, 2025, down by 2.53 yuan, a decline of 3.79% from the previous trading day [1] - The company operates in the biopharmaceutical industry, focusing on the research and commercialization of innovative drugs, with products covering oncology and autoimmune diseases [1] - Rongchang Biopharma has proprietary platforms for antibody fusion proteins, monoclonal antibodies, and bispecific antibodies, and is advancing multiple clinical studies in domestic and international markets [1] Group 2 - The innovative drug industry showed active performance in 2025, with the National Medical Products Administration approving over 20 Class 1 innovative drugs for market entry, marking the highest number in the past five years [1] - There has been frequent overseas licensing cooperation for domestic innovative drugs, with total transaction amounts exceeding 48.4 billion USD, indicating an accelerated trend of internationalization in the industry [1] - On July 31, 2025, the net outflow of main funds for Rongchang Biopharma was 76.38 million yuan, accounting for 0.73% of its circulating market value [2]